链激酶治疗老年急性心肌梗塞患者的临床分析

A clinical study on the use of intravenous streptokinase as thrombolytic therapy in aged patients with acute myocardial infarction

目的探讨链激酶(SK)静脉溶栓治疗对老年患者的影响。方法对138例链激酶(SK)静脉溶栓治疗的患者进行临床分析,按年龄分组,对溶栓后冠状动脉再通率、心脏事件发生率、病死率及出血并发症作临床分析。结果 >65岁组的患者其血管再通率、心脏事件发生率、病死率及出血并发症与≤65岁的患者比较无显著性差异(70.5％ vs.77.7％ P>0.05;40.9％vs.40.4％ P>0.05;15.9％vs.10.6％ P>0.05;11.4％vs.10.6％ P>0.05)。结论 SK静脉溶栓治疗老年急性心肌梗塞患者是安全可行的,但要视每位患者具体情况而定。

Objective To study the effect of intravenous streptokinase (SK) for thrombolytic therapy on aged patients with AMI. Methods One hundred and thiry - eight patients with definit AMI were treated by intravenous SK. They were di-vided into > 65yrs group and≤65yrs groups. Results There were no signiflcant differences in the repetfusion rate and the rate of occurrence of side effects in heart and death rate and complication of hemorrhage between > 65yrs group and≤s 55yrs group (70.5% vs.77.7% P>0.05; 40.9%vs. 40.4% P>0.05; 15.9% vs. 10.6% P>0.05; 11.4% vs.10.6% P> 0.05) . Conclusion It is safe that administering intravenous SK thrombolysis to patients who are over 65 yrs old, but it de-pends on patients' general condition.